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Abstract: This study deals with the process of optimization and synthesis of Poly(3-hydroxybutyrate)
microspheres with encapsulated Cl-amidine. Cl-amidine is an inhibitor of peptidylarginine deim-
inases (PADs), a group of calcium-dependent enzymes, which play critical roles in a number of
pathologies, including autoimmune and neurodegenerative diseases, as well as cancer. While Cl-
amidine application has been assessed in a number of in vitro and in vivo models; methods of
controlled release delivery remain to be investigated. P(3HB) microspheres have proven to be an
effective delivery system for several compounds applied in antimicrobial, wound healing, cancer,
and cardiovascular and regenerative disease models. In the current study, P(3HB) microspheres
with encapsulated Cl-amidine were produced in a size ranging from ~4–5 µm and characterized for
surface morphology, porosity, hydrophobicity and protein adsorption, in comparison with empty
P(3HB) microspheres. Cl-amidine encapsulation in P(3HB) microspheres was optimized, and these
were found to be less hydrophobic, compared with the empty microspheres, and subsequently
adsorbed a lower amount of protein on their surface. The release kinetics of Cl-amidine from the
microspheres were assessed in vitro and expressed as a function of encapsulation efficiency. There
was a burst release of ~50% Cl-amidine in the first 24 h and a zero order release from that point
up to 16 days, at which time point ~93% of the drug had been released. As Cl-amidine has been
associated with anti-cancer effects, the Cl-amidine encapsulated microspheres were assessed for the
inhibition of vascular endothelial growth factor (VEGF) expression in the mammalian breast cancer
cell line SK-BR-3, including in the presence of the anti-proliferative drug rapamycin. The cytotoxicity
of the combinatorial effect of rapamycin with Cl-amidine encapsulated P(3HB) microspheres was
found to be 3.5% more effective within a 24 h period. The cells treated with Cl-amidine encapsulated
microspheres alone, were found to have 36.5% reduction in VEGF expression when compared with
untreated SK-BR-3 cells. This indicates that controlled release of Cl-amidine from P(3HB) micro-
spheres may be effective in anti-cancer treatment, including in synergy with chemotherapeutic agents.
Using controlled drug-delivery of Cl-amidine encapsulated in Poly(3-hydroxybutyrate) microspheres
may be a promising novel strategy for application in PAD-associated pathologies.
Keywords: peptidylarginine deiminase inhibitor; Cl-amidine; Poly(3-Hydroxybutyrate) microspheres;
encapsulation; controlled drug delivery
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1. Introduction
Peptidylarginine deiminases (PADs) constitute a family of calcium-dependent en-
zymes, with five isoenzymes in mammals that are PAD1, 2, 3, 4 and PAD6. PADs induce
the post-translational deimination of arginine residues to produce citrulline in a calcium
dependent manner, leading to structural and functional changes in target proteins [1–3].
The different PAD isozymes display tissue-specific expression and preferences for specific
target proteins, although some are overlapping [4]. The PAD isozymes that have hitherto
gained most interest in relation to autoimmune pathologies, neurodegeneration and cancer
are PAD2 and PAD4 [2,4,5], whilst PAD3 has also gained considerable attention in relation
to CNS regeneration [6,7] as well as in CNS related cancers [8,9]. Both PAD2 and PAD4 are
linked to a range of cancers [3,9–11], and PAD3 has furthermore recently been highlighted
in aggressive brain and pancreatic cancers [8–10]. PAD2 is the most broadly expressed
isoform in tissues, including in the CNS, and is involved in CNS plasticity and transcription
regulation, whilst PAD4 is mainly localized in the white blood cells and epithelial cells
and is involved in chromatin decondensation, transcription regulation, tumorigenesis and
innate immunity [2,11–13].
In relation to the CNS, both PAD2 and PAD4 are activated during development, also
due to calcium oscillations, but are not normally activated in adults [11,14], whilst PAD3
has furthermore been associated with neuronal stem cells [15] and CNS regeneration [6,7].
However, both PAD2 and 4 have been found to play crucial roles in the development of
immune-mediated and/or neurodegenerative diseases due to calcium dysregulation and
the detection of increase in deiminated proteins in the CNS is associated with numerous
neurodegenerative diseases such as multiple sclerosis (MS), Alzheimer’s disease (AD) and
Parkinson’s disease (PD) [16–20].
One of the main consequences of post-translational deimination/citrullination medi-
ated by PADs in the CNS was initially the observation of roles in multiple sclerosis (MS) due
to the initiation and progression of autoimmune responses against the myelin sheath [18].
This is triggered due to neo-epitope exposure [21], leading to the development of this most
common chronic, neurodegenerative, autoimmune disease. Furthermore, in various stud-
ies carried out using preclinical animal models of MS; transgenic mice with multiple copies
of cDNA that encodes PAD2 [22] and mice with MOG-induced-experimental autoimmune
encephalomyelitis (EAE) [23], it was shown that the rapid progression of MS is mainly due
to PAD-mediated citrullination of myelin basic protein, which is the main component of
myelin sheath [2,24,25]. PAD2 overexpression accompanied with deiminated proteins was
also detected in the hippocampal region of Alzheimer’s patients [26,27], and furthermore,
increased protein deimination has been observed in pre-motor PD brains [19].
Roles for PADs in acute CNS injury have also been described, and PAD inhibition
using the pan-PAD inhibitor Cl-amidine was shown to effectively reduce brain injury
following hypoxic ischemic insult (HI) in a murine model [7,28]. Roles for PADs in CNS
regeneration were also demonstrated, showing that PAD3 contributed to the modulation
of secondary injury response following spinal cord damage and that Cl-amidine could
effectively promote CNS regeneration [6]. The pan-PAD inhibitor, Cl-amidine, [29,30]
is well established and has already been assessed in a number of in vitro and in vivo
models, including autoimmune diseases, cancer models and CNS neuroprotection with
potent neuroprotective effects [3,6–8,20,31–35]. In previous studies of breast cancer models,
Cl-amidine was reported to have anticancer effects either alone or in combination with
other anti-mitotic chemotherapeutic agents such as docetaxel [34,35]. The reported an-
ticancer effects of Cl-amidine administration involved the induction of cell cycle arrest
and apoptosis through the enhancement of p53 nuclear accumulation, which regulates the
expression of the OKL38 gene, a mediator of apoptosis [35,36]. In addition, Cl-amidine
co-administration with chemotherapeutic agents enhances their effects through promoting
the sensitization of cancer cells via extracellular vesicle (EV) modulation [34]. Furthermore,
both Cl-amidine and PAD-isozyme specific inhibitors have been found to be effective in
other in vitro cancer cell models such as glioblastoma and pancreatic cancer [8–10]. As
Int. J. Mol. Sci. 2021, 22, 12852 3 of 21
many of the above mentioned studies used single administration of Cl-amidine following
experimental injury, there is further need to develop methods and understanding for ap-
plication of controlled Cl-amidine delivery for application in disease models. This would
for example be important in relation to treatment in autoimmune diseases, progressive
neurodegenerative diseases, CNS damage and regeneration, as well as in cancer.
Therefore, the generation of a tailored delivery system for PAD inhibitors, including
Cl-amidine, is warranted. In the current study, an attempt to develop targeted delivery
approaches for Cl-amidine took advantage of using the polyhydroxyalkanoate (PHA)
biopolymers, which are already used and were previously validated in regenerative stud-
ies [37–43]. Furthermore, a proposed anti-cancerous effect of Cl-amidine was assessed,
upon its co-administration with rapamycin, through investigating its effect on VEGF ex-
pression in a mammalian breast cancer cell line (SK-BR-3). VEGF has been extensively
reported as a pivotal promoter of cancer cells metastasis through mediating angiogen-
esis [44–49]. VEGF has furthermore been attributed as a key player in CNS injury and
regeneration [50–52].
Currently, drug encapsulation into polymeric micro- and nano-particles is the most
commonly used drug delivery method. Micro/nano-particle encapsulation provides con-
trolled and sustained drug release, which warrants an efficient pharmacological response.
Among the well-established production techniques of micro/nanoparticles are coacerva-
tion, spray drying and numerous emulsion techniques [53]. Besides, various supercritical
fluids-based techniques have further been developed to overcome the inconsistency within
the produced particle sizes along with other drawbacks that could be associated with the
conventional production methods [54–56]. In these techniques, carbon dioxide (scCO2)
is the most successfully used supercritical fluid that can be applied either for solvent or,
more commonly, for antisolvent co-precipitation of the polymeric carrier along with the
drug as fine powders [57,58]. The supercritical fluid-based co-precipitation technique,
in addition to the type of polymeric carrier used, produces a bimodal release pattern of
the encapsulated drug [54,59,60]. The release pattern is characterized by an initial burst
release for immediate symptoms alleviation, followed by a sustained release which is the
pattern of choice for chronic conditions. This antisolvent co-precipitation technique was
not applied within this study due to the insolubility of the solute drug, Cl-amidine, within
the organic solvent, chloroform.
In this current study, PHA biopolymers were used [61]. Initially, PHA biopolymers
are produced intracellularly by certain bacterial species through fermentation in the form
of a storage material. Consequently, these polymers are purified, extracted and remod-
elled into either micro or nanoparticles by applying an emulsion methodology [62]. The
family of Polyhydroxyalkanoates (PHAs) is widely used in medical applications and is
currently considered as one of the most promising group of biopolymers due to being
highly biocompatible, bioresorbable, non-cytotoxic and non-carcinogenic [63]. This high
safety profile favours the PHAs over other biodegradable polymers such as: polylactic
acid (PLA) and poly(lactic-co-glycolic acid) (PLGA) which produce acidic by-products that
provoke immune responses besides rendering the patients prone to toxicity [63]. PHAs
are water insoluble linear polyesters of 3, 4, 5 and 6-hydroxyacids, synthesized by var-
ious microorganisms, through fermentation using limited nitrogen sources and excess
carbon [38].
Both Poly(3-hydroxyoctanoate), P(3HO) and Poly(3-hydroxybutyrate), P(3HB), which
are produced by Pseudomonas mendocina and the modified Bacillus subtilis OK2 strain respec-
tively, are members of PHAs which are able to exhibit high efficacy when used in regenera-
tive studies [64–71]. Both P(3HO) and P(3HB) exhibit outstanding outcomes when used
as supporting scaffolds in cardiac, nerve, bone and skin tissue engineering [69,70,72–74].
In addition, P(3HB) has been proven to provide a well-tailored vehicle for drug delivery
when used to formulate drug encapsulated microspheres, both in terms of encapsulation
efficiency and drug release [39,40,75].
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Thus, for novel drug-development, Cl-amidine was used as an exemplar PAD inhibitor
in the current study for assessment of effectivity of PAD-inhibitor encapsulation in a
controlled drug-delivery system comprising P(3HB) microspheres, which has previously
been established as a safe and effective delivery method in various disease models. This
novel drug delivery system may offer a sustained and tailored release rate according to the
disease treated and provide longer term, safe release of the pan-PAD inhibitor Cl-amidine
in a range of chronic disorders and cancer.
2. Results
2.1. P(3HB) Microsphere Optimization and Characterization
Cl-amidine was encapsulated in P(3HB) microspheres according to previously estab-
lished methods [75], and the process was further optimized to obtain smaller microspheres
of size ranging between 4–5 µm and maximum encapsulation efficiency according to the
conditions presented in Table 1. Cl-amidine encapsulated P(3HB) microspheres corre-
sponding to condition 3 (Table 1) were used for further characterization since this was the
optimum condition producing the desired microsphere diameter and maximum encapsu-
lation efficiency, compared with the preceding conditions. The results of these were then
compared with empty microspheres which were used as control, in addition to rhodamine
encapsulated P(3HB) microspheres which were used as another type of control due to the
hydrophilicity of rhodamine [76,77] beside its fluorescent nature that could be used for
future in vivo work, as discussed in Section 4.2.
Table 1. Process optimization of empty control, Cl-amidine and control rhodamine encapsulated P(3HB) microspheres.








1 Cl-amidine 2 0.013 0.5% 300
2 Cl-amidine 2 0.013 1% 300
3 Cl-amidine 2 0.0065 1% 1200
3 RhodamineControl 2 0.0065 1% 1200
3 None/Control - 0.0065 1% 1200
2.2. Surface Morphology of the Cl-Amidine Encapsulated P(3HB) Microspheres Using SEM
The SEM images obtained from the production of P(3HB) microspheres with encap-
sulated Cl-amidine, according to the different conditions presented in Table 1, are shown
in Figure 1A–C. The surface morphology of the microspheres produced under the three
conditions appears to be uniform as most of the particles are spherical in shape and ex-
hibit porosity. Nevertheless, some polymeric flakes are present, mainly in condition 1
(Figure 1A). As for the particle size polydispersity, both conditions 1 (Figure 1A) and
2 (Figure 1B) showed a noticeable degree of polydispersity among the majority of the
microspheres produced, whilst the majority of microspheres produced under condition
3 (Figure 1C) were monodisperse. Both conditions 1 (Figure 1A) and 2 (Figure 1B) pro-
duced relatively large sized microspheres with diameters of 40 and 50–60 µm, respectively.
Conversely, P(3HB) microspheres produced under condition 3 were within the desired
diameter range of 4–5 µm. This relatively low diameter range indicates increased surface
area-to-volume ratio of the microspheres which directly increases the rate of encapsulated
drug release. Thus, condition 3 was considered as the most optimal one and was further
used in the continued experiments.
Int. J. Mol. Sci. 2021, 22, 12852 5 of 21




Figure 1. SEM images showing the surface morphology of Cl-amidine encapsulated P(3HB) 
microspheres produced under three different fabrication conditions. (A) Representative image of 
polydisperse microspheres and microsphere flakes produced under condition 1 (average diameter 
= 40 µm). (B) Representative image of polydisperse microspheres produced under condition 2 
(average diameter = 50–60 µm); (C) Representative image showing the desired monodispersed 
P(3HB) microspheres with Cl-amidine encapsulated produced under condition 3 (average diameter 
= 4–5 µm). The scale bar represents 20 µm in all figures, and all images are taken at 800.0× 
magnification. The size of the scale bar was set as a reference to compare the Cl-amidine containing 
P(3HB) microsphere sizes produced under the 3 different conditions. 
2.3. Fourier Transform Infrared Spectroscopy (FTIR) of Cl-Amidine Encapsulated P(3HB) 
Microspheres  
The FTIR spectra of Cl-amidine encapsulated P(3HB) microspheres provided two 
distinct peaks at a similar range of wavelengths as those produced by P(3HB), indicating 
the absence of impurities (Figure 2). The FTIR spectra obtained with the microspheres 
exhibited two distinct peaks at wave numbers of 1719.96 cm−1 corresponding to the ester 
carbonyl group and at 1275.92 cm−1 corresponding to the methyl group (Figure 2), both of 
which are characteristic of the small-chain-length polyhdroxyalkanoates (SCL-PHAs), to 
which the P(3HB) belongs [78]. Supplementary Figure S1 furthermore shows an overlay 
of FTIR spectra of both empty and P(3HB) microspheres with Cl-amidine encapsulated; 
no wavelength shift was identified for the microspheres containing Cl-amidine, compared 
with empty microspheres, indicating absence of impurities (Supplementary Figure S1). 
Cl-amidine absorption spectrum was used to detect its wavelength of maximum 
absorbance (327 nm) required for further testing using UV-spectrophotometry 
(Supplementary Figure S2), whilst no further assessment by FTIR was carried out for Cl-
amidine alone. 
Figure 1. SEM images showing the surface morphology of Cl-amidine e capsulated P(3HB) mi-
crospheres produced under three different fabrication conditions. (A) Representative image of
polydisperse microspheres and microspher flakes produced under condition 1 (average diameter =
40 µm). (B) Representative image of polydisperse microspheres produced under condition 2 (average
diameter = 50–60 µm); (C) Representative image showing the desired monodispersed P(3HB) micro-
spheres with Cl-amidine encapsulated produced under condition 3 (average diameter = 4–5 µm).
The scale bar represents 20 µm in all figures, and all images are taken at 800.0× magnification. The
size of the scale bar was set as a reference to compare the Cl-amidine containing P(3HB) microsphere
sizes produced under the 3 different conditions.
2.3. Fourier Transform Infrared Spectroscopy (FTIR) of Cl-Amidine Encapsulated
P(3HB) Microspheres
The FTIR spectra of Cl-amidine encapsulated P(3HB) microspheres provided two dis-
tinct peaks at a similar range of wavelengths as those produced by P(3HB), indicating the
absence of impurities (Figure 2). The FTIR spectra obtained with the microspheres exhibited
two distinct peaks at wave numbers of 1719.96 cm−1 corresponding to the ester carbonyl
group and at 1275.92 cm−1 corresponding to the methyl group (Figure 2), both of which are
characteristic of the small-chain-length polyhdroxyalkanoates (SCL-PHAs), to which the
P(3HB) belongs [78]. Supplementary Figure S1 furthermore shows an overlay of FTIR spec-
tra of both empty and P(3HB) microspheres with Cl-amidine encapsulated; no wavelength
shift was identified for the microspheres containing Cl-amidine, compared with empty
microspheres, indicating absence of impurities (Supplementary Figure S1). Cl-amidine
absorption spectrum was used to detect its wavelength of maximum absorbance (327 nm) re-
quired for further testing using UV-spectrophotometry (Supplementary Figure S2), whilst
no further assessment by FTIR was carried out for Cl-amidine alone.
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Figure 2. FTIR of Cl-amidine encapsulated P(3HB) microspheres. The FTIR spectra of Cl-amidine encapsulated P(3HB) 
microspheres exhibiting two distinct peaks at wave numbers of 1719.96 and 1275.92 cm−1, which correspond to the ester 
carbonyl and methyl groups, respectively, both of which are characteristic of the P(3HB) biopolymer used with which the 
microspheres are produced. 
2.4. Porosity of Microspheres 
All of the P(3HB) microspheres, the empty control, the control with encapsulated 
rhodamine and with encapsulated Cl-amidine, produced under the same conditions 
(condition 3 in Table 1) exhibited internal porosity which was measured using the 
following equation: 
ε = (W2−W3−Ws)/(W1−W3). 
The average percentages of porosity for the empty control, rhodamine encapsulated 
control and Cl-amidine encapsulated P(3HB) microspheres were 52%, 56% and 73%, 
respectively. This percentage porosity exhibited by the P(3HB) microspheres with 
encapsulated Cl-amidine was significantly higher than that of the empty control 
microspheres (p = 0.014), whilst there was no significant difference when compared to the 
control microspheres with rhodamine encapsulated (Figure 3). 
Figure 2. FTIR of Cl-amidine encapsulated P(3HB) microspheres. The FTIR spectra of Cl-amidine
encapsulated P(3HB) microspheres exhibiting two distinct peaks at wave numbers of 1719.96 and
1275.92 cm−1, which correspond to the ester carbonyl and methyl groups, respectively, both of which
are characteristic of the P(3HB) biopolymer used with which the microspheres are produced.
2.4. Porosity of Microspheres
All of the P(3HB) microspheres, the empty control, the control with encapsulated
rhodamine and with encapsulated Cl-amidine, produced under the same conditions (con-
dition 3 in Table 1) exhibited internal porosity which was measured using the follow-
ing equation:
ε = (W2−W3−Ws)/(W1−W3).
The average percentages of porosity for the empty control, rhodamine encapsulated
control and Cl-amidine encapsulated P(3HB) microspheres were 52%, 56% and 73%, respec-
tively. This percentage porosity exhibited by the P(3HB) microspheres with encapsulated
Cl-amidine was significantly higher than that of the empty control microspheres (p = 0.014),
whilst there was no significant difference when compared to the control microspheres with
rhodamine encapsulated (Figure 3).
2.5. Surface Hydrophobicity and Residual Percentage PVA
The determination of surface hydrophobicity of the control empty P(3HB) micro-
spheres and those with encapsulated rhodamine and Cl-amidine, produced under condi-
tion 3 (Table 1), was carried out by comparing the amount of Rose Bengal dye adsorbed
per each mg of the three groups of microspheres. The amount of Rose Bengal dye bound
to each mg of the three groups of microspheres increased as the percentage of the surface
bound residual PVA decreased (Figure 4A,B). For instance, at the maximum Rose Bengal
dye concentration used (50 µg/mL), the empty control P(3HB) microspheres exhibited
the highest adsorption by adsorbing 9.42 µg/mg of the dye (Figure 4A) while retaining
the lowest percentage of residual PVA on its surface which is 0.221% (Figure 4B). As for
the Cl-amidine containing P(3HB) microspheres which adsorbed 5.26 µg/mg (Figure 4A),
the microspheres exhibited a percentage of 0.226% of residual PVA (Figure 4B). Finally, the
rhodamine encapsulated control microspheres showed the least adsorption of 4.9 µg/mg
of the dye (Figure 4A) whilst exhibiting the highest percentage of surface-bound residual
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PVA that reached 0.312% (Figure 4B).The statistical analysis showed insignificant differ-
ences between the empty control and Cl-amidine containing microspheres in terms of
the residual percentage PVA. However, comparing the rhodamine containing control mi-
crospheres to both, the empty control and microspheres with encapsulated Cl-amidine
revealed a significantly higher percentage of residual PVA as indicated by p values of
0.027 and 0.012, respectively. Conversely, there were insignificant differences between the
three produced batches of microspheres on measuring the surface hydrophobicity upon
performing ANOVA analysis (p value 0.06). The average amount of dye adsorbed by
empty control P(3HB) microspheres, upon applying increasing dye concentrations, was
5.9 µg/mg compared to 2.8 and 2.2 µg/mg for microspheres with encapsulated Cl-amidine
and rhodamine, respectively.




Figure 3. Porosity assessment of P(3HB) microspheres with encapsulated drug. The percentage 
porosity exhibited by empty, rhodamine and Cl-amidine containing P(3HB) microspheres was 52%, 
56% and 73%, respectively; exact p values are indicated, and error bars indicate standard deviation 
(SD); * p ≤ 0.05. 
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µg/mg of Rose-Bengal dye (Figure 5). Conversely, control rhodamine containing P(3HB) 
microspheres adsorbed the least amount of BSA on the surface represented by 1.19 µg/mg 
while simultaneously possessing the least surface hydrophobicity (4.9 µg/mg) measured 
using the rose Bengal dye adsorption assay. As for the Cl-amidine containing P(3HB) 
microspheres, these adsorbed 1.37 µg/mg of BSA which is an intermediate value in 
between the two other types of microspheres and the same applied to its surface 
hydrophobicity (5.26 µg/mg) (Figure 5). The protein adsorption values of empty control 
microspheres were significantly higher by 43% (p value = 0.001) and 53% (p value = 0.0004) 
when compared to microspheres with encapsulated Cl-amidine and rhodamine, 
respectively, whilst no significant difference was seen between Cl-amidine and 
rhodamine containing spheres. 
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spheres adsorbed the least amount of BSA on the surface represented by 1.19 µg/mg while
simultaneously possessing the least surface hydrophobicity (4.9 µg/mg) measured using
the rose Bengal dye adsorption assay. As for the Cl-amidine containing P(3HB) micro-
spheres, these adsorbed 1.37 µg/mg of BSA which is an intermediate value in between
the two other types of microspheres and the same applied to its surface hydrophobicity
(5.26 µg/mg) (Figure 5). The protein adsorption values of empty control microspheres were
significantly higher by 43% (p value = 0.001) and 53% (p value = 0.0004) when compared
to microspheres with encapsulated Cl-amidine and rhodamine, respectively, whilst no
significant difference was seen between Cl-amidine and rhodamine containing spheres.
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2.6. Protein Adsorption Assay (Bradford’s Assay) 
The empty P(3HB) microspheres exhibited the highest protein adsorption of 2.4 
µg/mg of bovine serum albumin (BSA) on its surface which corresponded to retaining 9.42 
µg/mg of Rose-Bengal dye (Figure 5). Conversely, control rhodamine containing P(3HB) 
microspheres adsorbed the least amount of  n the surface r present d by 1.19 µg/mg 
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Figure 5. Protein adsorption assay of empty, rhodamine and Cl-amidine P(3HB)-containing micro-
spheres. This figure shows the amount of protein (BSA) adsorbed on the surface of each mg of the
three types of microspheres (exact p values are indicated, the error bars indicate SD); ** p ≤ 0.01,
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2.7. Cl-Amidine Encapsulation Efficiency and In Vitro Release Kinetics
Cl-amidine release from the P(3HB) microspheres was assessed and expressed as a
function of encapsulation efficiency which was found to be 48.10 ± 0.69% for the micro-
spheres. There was a burst release of ~50% in the first 24 h followed by a zero order release
from that point up to 16 days, by which point, ~93% of the drug is released (Figure 6).
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2.8. Cell Culture
The mammalian breast cancer cell line SK-BR-3 was treated with the anti-proliferative
drug rapamycin, with and without the presence of Cl-amidine encapsulated P(3HB) mi-
crospheres. The viability of the breast cancer cell line was found to be 91.1%, 83.2% and
79.7% after being treated with P(3HB) microspheres with encapsulated Cl-amidine, with
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rapamycin, and with Cl-amidine containing microspheres in combination with rapamycin,
respectively (Figure 7). This showed that the combinatorial effect of rapamycin together
with the Cl-amidine containing microspheres, on reducing the breast cancer cell line vi-
ability, surpassed the effect of the anti-proliferative drug alone by 3.5% (Figure 7). This
was further confirmed by the statistical tests which revealed significant differences be-
tween the three groups where the combinatorial effect showed p values of 2 × 10−8 and
1 × 10−5 when compared to treatment of the cell line with either Cl-amidine containing
microspheres or rapamycin alone, respectively. However, rapamycin application alone
exhibited a significant reduction in cell viability compared to the effect of microspheres
containing Cl-amidine (p value = 4 × 10−7).




Figure 7. The effect of a combined application of P(3HB) microspheres with encapsulated Cl-
amidine along with the anti-proliferative drug (Rapamycin) on the viability of SK-BR-3 breast cancer 
cells. The bars indicate control (untreated) cells, compared with microspheres with encapsulated Cl-
amidine, free rapamycin and Cl-amidine containing spheres in combination with free rapamycin 
(exact p values are indicated, the error bars indicate SD); *** p ≤ 0.001. 
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3. Discussion
The current study was aimed at encapsulating the pan-PAD inhibitor Cl-amidine into
P(3HB) microspheres for controlled drug delivery, which may be applicable in a range of
PAD-related pathologies, including inflammatory, autoimmune and neurodegenerative
diseases, as well as cancer. Here, the technique of choice was solid-oil-in-water (s/o/w)
emulsion for the preparation of P(3HB) microspheres, which was carried out under three
different conditions which varied in the polymer and surfactant concentrations, as well
as the stirrer speed, in order to optimize maximum encapsulation efficiency within the
microspheres. For microsphere preparation, polyvinyl alcohol (PVA) was used as the
emulsifying surfactant to stabilize the double emulsion system through promoting the
P(3HB) precipitation in the form of microspheres rather than its precipitation as a polymeric
mass as previously observed in the absence of PVA [79,80]. It has been reported in several
studies that the varying PVA concentrations can affect the produced microspheres in terms
of particle size and encapsulation efficiency. In the current study, the applied concentrations
of PVA in both the internal and external emulsion phases were 0.5% w/v for condition 1 and
1% w/v for both conditions 2 and 3 (Table 1). This specific PVA range was selected since
previously applied PVA concentrations below 0.5% w/v failed to stabilize the organic phase
droplets within the external aqueous phase of the emulsion, leading to their adherence
to the magnetic stirrer. Conversely, raising the concentration above 1% w/v rendered it
difficult to obtain the desired size range of the microspheres due to the elevated viscosity
of the external emulsion phase, owing to the high molecular weight of PVA [79]. It was
thus expected that doubling the PVA concentration from 0.5% w/v in condition 1 to
1% w/v in condition 2 for improved emulsion stabilization, whilst retaining the same
polymer concentration of 0.013 g per mL of chloroform and stirring speed of 300 rpm for
both conditions, would result in the production of microspheres with increased particle
size. SEM images of microspheres produced under condition 2 showed a larger diameter
range of 50–60 µM (Figure 1A) compared to condition 1 which resulted in a diameter
average of 40 µM (Figure 1A). This is explained by the relatively increased viscosity of
the external emulsion phase owing to doubling the PVA concentration, thus requiring
higher shear force to produce microspheres of a smaller size range [75]. Consequently,
to balance this effect, the stirrer speed was increased from 300 rpm in conditions 1 and 2
to 1200 rpm in condition 3 while using the 1% w/v PVA concentration. Applying this, a
significantly smaller size range of the P(3HB) microspheres was produced owing to both
the higher shear forces of the increased stirring speed [81,82] and using the higher PVA
concentration (1% w/v) which, together, prevented the coalescence of the double emulsion
droplets into larger microparticles [83]. In addition, previous studies [84,85] stated that
the polymer concentration in the emulsion phase is directly proportional to the solution
viscosity. Thus, decreasing the polymer concentration in this condition (condition 3) to
half of its value, from 0.013 g/mL to 0.0065 g/mL, reduced the solution viscosity and
consequently facilitated its dispersion into smaller microspheres than those produced
under both previous conditions. Furthermore, the PVA concentration used within both
the internal and external emulsion phases directly affects the distribution pattern and the
encapsulation efficiency of Cl-amidine inside the P(3HB) microspheres. It was reported
that increasing the PVA concentration, within both phases, helps to promote the uniform
distribution of the encapsulated drug along with improving its encapsulation efficiency.
The latter is attributed to the increased availability of PVA in the initial interface between the
internal aqueous phase and organic phase as well as covering the second interface between
the organic phase and the external aqueous phase which decreases the surface tension
significantly and thus prevents leakage of the encapsulated hydrophilic drug from the
hydrophobic polymeric system during microspheres production [83,85]. Besides, applying
a high concentration of PVA in the internal emulsion phase decelerates the coalescence of
internal emulsion droplets; hence, it improves the encapsulation efficiency of the entrapped
drug [85]. Accordingly, it is suggested that using the higher PVA concentration of 1% w/v
in condition 3 contributed to achieving a proper encapsulation efficiency of the hydrophilic
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Cl-amidine within the P(3HB) microspheres. In addition, according to previous studies,
the applied concentration of PVA is directly correlated to its residual amount found on the
surface of the produced microspheres. Since identifying the amount of residual PVA was
carried out for the three types of microspheres produced simultaneously under condition 3,
using the same PVA concentration of 1% w/v; thus, the resulting percentage surface residual
PVA among the three species was within a close range of 0.22–0.31% [75]. This range is
similar to the results obtained by Zielhuis et al. [86] who reported a range of 0.2–0.3% of
residual PVA on PLGA microspheres, whilst representing almost half the values reported
by Francis et al. [75], which reached 0.5–0.6% on the surface of P(3HB) microspheres upon
applying a PVA concentration of 1% w/v [75,86]. The presence of residual PVA identified
on the microsphere surface is attributed to its molecular arrangement as an amphiphilic
surfactant across the organic and aqueous phases of the double emulsion to reduce the
surface tension. During the microsphere production, the hydrophobic tail of the PVA binds
irreversibly to the polymeric surface within the organic phase upon reaching the critical
micelle concentration, whilst retaining its hydrophilic head attached on the microspheres
surface despite the final washing step [87–90]. Consequently, the percentage residual
PVA represents its surface-exposed hydrophilic portion, which is inversely proportional
to the surface hydrophobicity and protein adsorption properties of the produced P(3HB)
microspheres as revealed by this study. According to the current results, at the maximum
Rose Bengal dye concentration used (50 µg/mL) to determine surface hydrophobicity, the
empty control P(3HB) microspheres exhibited the highest adsorption (Figure 4a) while
retaining the lowest percentage of residual PVA on its surface (Figure 4b). Conversely,
the control rhodamine encapsulated microspheres showed the least adsorption of the dye
(Figure 4a) alongside exhibiting the highest percentage of surface bound residual PVA
(Figure 4b) while the microspheres with encapsulated Cl-amidine adsorbed an amount of
Rose-Bengal dye which lay in the middle between the other two types of microspheres and
the same applied to its percentage of surface bound residual PVA. This inverse relationship
of residual PVA and surface hydrophobicity was also confirmed by previous studies [75].
As for the protein adsorption, the current study showed that a higher surface hy-
drophobicity was directly correlated to higher protein (BSA) adsorption onto the surface of
the P(3HB) microspheres (Figure 5). This could be explained by the outcomes of a recent
study conducted by Fang et al. [91] who applied the Hansen solubility parameters (HSP)
as an indicator to identify the polarity of the surface-adsorbed BSA versus the native,
unbound BSA [91]. The study revealed proximity between the HSP values of the BSA
adsorbed onto polymeric surfaces and those of the hydrophobic Zein protein. In addition,
these calculated values proved that the surface-adsorbed BSA is much more hydrophobic
compared to the native, unbound BSA. This altered hydrophobic conformation is attributed
to BSA denaturation upon polymeric surface adsorption which results in displaying its
hydrophobic core, rather than its hydrophilic shell, onto the polymeric surface. Hence, the
BSA adsorption onto the P(3HB) microspheres was inversely proportional to their residual
PVA content and directly dependent on their surface hydrophobicity [91].
Since the main aim of this study was to attempt a controlled release and delivery
system for Cl-amidine, the encapsulation efficiency and in vitro release kinetics of Cl-
amidine were further assessed. Cl-amidine release from the P(3HB) microspheres was
expressed as a function of encapsulation efficiency which was found to be 48.10 ± 0.7%
within the microspheres. This value is considered among the maximum encapsulation
efficiencies (EE) reported of hydrophilic drugs encapsulated into various polymeric mi-
cro/nanospheres. For instance, the EE of the hydrophilic doxycycline in 5002A PLGA
microspheres reached a maximum range of (42.12% ± 4.66) to (45% ± 6.31) despite the
reported optimization of almost all of the various formulation parameters [92]. Besides,
the EE of doxorubicin within poly(3-hydroxybutyrate-co-3-hydroxyvalerate) nanoparti-
cles was 22.9% ± 1.7 [93], whilst encapsulating vancomycin within the same polymeric
microspheres achieved an EE of 27.3% [94]. A slightly higher value of vancomycin EE
was reported in case of using poly(lactide-co-glycolide)– methoxypoly(ethylene glycol)
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microspheres which is equal to 55.2% [95]. Additionally, loading of alendronate sodium
into polycaprolactone based nanoparticles achieved an EE of 34% [96], whilst P(3HB) mi-
crospheres, similar to those applied in this study, with encapsulated gentamicin exhibited
a similar EE of 48% [75]. However, an outlier to these reported values was the EE of
novel oligo (3-hydroxybutyrate-graft-hyaluronic acid) Oligo (3HB-g-HA) microspheres
with encapsulated gentamicin, which reached around 71.3 ± 2.5 % [97]. Thus, among
the future perspectives of this research study would be the improvement of EE of the hy-
drophilic Cl-amidine through testing a number of mechanisms reported by recent literature
which include pH-adjustment of the external aqueous phase of the emulsion system and
applying a small-scale liquid–liquid partitioning to provide the maximum concentration of
Cl-amidine free-base (unionized form) in the organic polymeric phase [98].
Following the EE, a pivotal element of the polymeric drug delivery systems was
addressed which is porosity. Porosity was the key determinant of Cl-amidine diffusivity
and release from within the P(3HB) microspheres [99]. Due to the hydrophilic nature of
Cl-amidine (70 mg/mL solubility in water according to Selleckchem and Merck indices),
its molecules tend to form a honeycomb porous structure across certain areas within the
microsphere matrices which contain the formed water channels upon solvent evaporation
during microsphere production, where Cl-amidine is efficiently distributed, encapsulated
and further released through accelerating the water uptake and thus penetration into the
encapsulating microspheres [75,95]. This honeycomb porous structure is formed while
applying the double emulsion–solvent evaporation technique for the production of the
P(3HB) microspheres with hydrophilic Cl-amidine as well as the hydrophilic rhodamine
encapsulated control [39,100]. Initially, the aqueous phase containing either dissolved Cl-
amidine or rhodamine is dispersed into an organic phase of the P(3HB) polymer, dissolved
into chloroform, forming the first water-in-oil (w1/o) emulsion. Then, this (w1/o) emulsion
is also dispersed into a second aqueous phase containing the hydrophilic, emulsifying
surfactant, PVA, to finally form the double emulsion system (w1/o/w2). This system
then undergoes solvent evaporation of the chloroform. During chloroform evaporation,
the P(3HB) polymer shrinks towards the core of the emulsion forming microdroplets
which constitute the honeycomb porous structure that contributes to the increased system
porosity compared to the empty control P(3HB) microspheres produced using a single
emulsion technique. Besides, this specific structure is reported to be optimal for efficient
encapsulation and release of the highly hydrophilic drugs. In addition, the outermost layer
of the precipitating P(3HB) polymer also forms holes through which either the encapsulated
Cl-amidine or rhodamine could be partially released. Consequently, this double emulsion-
solvent evaporation technique has been repeatedly used in several studies to improve the
entrapment and encapsulation efficiency of various hydrophilic drugs [85,101].
Another mechanism of Cl-amidine release was through the biodegradation process of
the P(3HB) microspheres. P(3HB) biodegradation takes place through surface erosion due
to the crystallinity and hydrophobicity of the P(3HB) polymeric backbone [102]. This hy-
drophobicity contributes to the relatively slow rate of water penetration into the polymeric
matrix. Consequently, the vast majority of the microspheres biodegradation process occurs
at the surface in the form of layer-by-layer hydrolysis, a process which could be described
as the hydrolytic peeling of the polymeric microspheres from the surface inwards which is
accompanied by the release of the encapsulated drugs entrapped within each layer, until
the polymeric matrix experiences mass loss [103–105]. Thus, this mechanism of surface
erosion is a desirable element of the polymeric drug delivery system since it contributes
to achieving a stable, zero-order pattern of sustained drug release which maintains the
release of a constant amount of the encapsulated drug from within the microspheres, per
unit time, regardless of the initial drug concentration [106,107]. According to the current
study results, there was a burst release of ~50% of Cl-amidine in the first 24 h attributed to
the surface associated drug [95]. This was then followed by a slower phase of zero order
release from that point up to 16 days, by which point approximately 93% of the drug had
been released (Figure 6).
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This indicated that the Cl-amidine encapsulated within the P(3HB) microspheres
can be used as a new delivery system for targeted Cl-amidine release, at controlled rates,
over longer periods of time, ranging from days to weeks. Consequently, this could pro-
vide novel application approaches for PAD inhibition in autoimmune diseases, cancer,
as well as in neurological conditions, where Cl-amidine has previously been shown to
be neuroprotective in CNS injury [6,7]. As deimination is associated with a range of
neurodegenerative pathologies including AD, MS and PD [3,19,22,23,26], the prospect of
controlled longer-term delivery of PAD inhibitors, including Cl-amidine may offer novel
treatment approaches.
In addition to the established neuroprotective roles of Cl-amidine, its anticancer
effects have also been investigated in several studies. For instance, Cl-amidine acts as an
effective modulator of extracellular vesicle release and cargo content from cancer cells,
also enhancing the efficiency of chemotherapeutic agents such as 5-fluorouracil (5-FU) and
TMZ in prostate, breast and brain cancer [3,8,33,34]. Furthermore, Cl-amidine contributes
to cancer cell apoptosis through induction of p53 nuclear accumulation, which in turn,
causes overexpression of the OKL38 gene, an apoptosis mediator [36,46].
In our current study, the mammalian breast cancer cell line SK-BR-3 was treated
with the anti-proliferative drug rapamycin with and without the presence of P(3HB)
microspheres with encapsulated Cl-amidine. The effect of combining rapamycin with
microspheres with encapsulated Cl-amidine showed a 3.5% reduction in breast cancer
cell viability in a 24 h period compared with cells treated with rapamycin only (Figure 7).
Thus, Cl-amidine released from the microspheres could effectively sensitise cancer cells to
chemotherapy and this may offer novel approaches for the use of controlled delivery of
Cl-amidine in cancer. Furthermore, an effect of P(3HB) microspheres with encapsulated
Cl-amidine on tumour vascularization and metastasis was assessed as a function of VEGF
expression. SK-BR-3 cells treated with Cl-amidine containing P(3HB) microspheres were
indeed found to have a significantly reduced expression of VEGF (by 36.54%), when com-
pared with untreated cells (Figure 8). Future work will aim at assessing the effectivity of
the P(3HB) microspheres with encapsulated Cl-amidine in vivo, alongside further opti-
mization for encapsulation efficiency and application in various disease models. This type
of controlled delivery system may also be applicable for other PAD inhibitors, including
isozyme-specific PAD inhibitors, with potentially tailored application for different diseases.
4. Materials and Methods
4.1. Materials
P(3HB) was produced according to previously established methods [43] and was
isolated using the soxhlet extraction method from the Gram-positive bacteria Bacillus subtilis
OK2 strain which was previously provided as a gift from Prof Fujio Kawamura, Department
of Life Sciences, Rikkyo University, Japan. All the chemicals used for the growth of Bacillus
subtilis OK2 strain, and the polymer extraction, were purchased from Sigma-Aldrich
Co (Gillingham, UK) and VWR Chemicals (Poole, UK). The kits and reagents used for
characterization of the microspheres were purchased from Bio-Rad Laboratories, Inc.
(Watford, UK), and Thermo Fisher Scientific (Hemel Hempstead, UK). The PAD inhibitor
Cl-amidine (Calbiochem, 506282) was obtained from Merck (Darmstadt, Germany).
4.2. Production of P(3HB) Microspheres with Encapsulated Rhodamine and Cl-Amidine
Synthesis of P(3HB) microspheres was carried out using a solid-in-oil-in-water emul-
sion technique. Different P(3HB) solutions in chloroform were prepared by dissolving
0.13 g of the polymer in either 10 or 20 mL of chloroform, in airtight bottles, overnight to
ensure complete dissolution. Then, the polymer solution was homogenized for duration
of 5 min using a homogenizer mixer. This was then transferred, in a drop-wise manner,
to 40 mL of either 0.5% or 1% w/v of aqueous polyvinyl alcohol (PVA) solution, stirred
at 600 rpm, to form the aqueous first solid-in-oil emulsion. In case of drug encapsulated
microspheres, this PVA solution would contain 2 mg of either dissolved rhodamine or Cl-
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amidine. P(3HB) microspheres with encapsulated rhodamine were produced as a control
due to its hydrophilic nature, similar to Cl-amidine, and thus the physical characteristics
of the microspheres could be compared [76,77]. In addition, rhodamine is a fluorescent
dye which would allow imaging of the P(3HB) microsphere localization upon in-vivo
testing using confocal microscopy (future work). Finally, the formed emulsion would
be vortexed for 10 min and homogenized for 15 min using a homogenizer mixer before
its dispersion into an external aqueous phase of 200 mL PVA solution. Hence, the sec-
ond oil-in-water emulsion was formed which was then stirred at either 300 or 1200 rpm
for 4 h to allow evaporation of the chloroform, used as the solvent. Consequently, the
empty P(3HB) microspheres with encapsulated rhodamine/Cl-amidine were produced
and centrifuged at a speed of 4600 rpm (g = 2370) for 20 min. The supernatant was then
discarded before the microspheres were washed with water and then subjected to a second
centrifugation cycle, frozen at 4 ◦C and finally freeze dried (Savant Modulyo D Freeze
drier, Thermoelectron Corp, Cheshire, UK). This double emulsion method was applied
since both the encapsulated compound (Cl-amidine) and control (rhodamine) drugs are
hydrophilic [39,75,100,108].
4.3. Characterization of P(3HB) Microspheres with and without Encapsulated Rhodamine
or Cl-Amidine
4.3.1. Surface Morphology and Microstructure Characterization
A JOEL 5610LV scanning electron microscope (SEM) was used to carry out the micro-
structural as well as the surface morphology studies on the samples of microspheres.
Aluminium stubs with 8 mm diameter were used on which the samples were placed to get
coated with gold by EMITECH-K550, a gold spluttering device. The operating pressure
and deposition current of 7 × 10−2 bar and 20 mA, respectively, were used for 2 min. Then,
to prevent the polymer incineration by the beam heat, the maximum acceleration voltage
of 15 kV was applied while taking the SEM images (Carried out at UCL Eastman Dental
Institute, London, UK).
4.3.2. Porosity
Liquid displacement method was used for measuring the microsphere porosity
(ε) [109]. The weight of a measuring cylinder was determined before and after adding 5 mL
of methanol. To this point, a specific weight of microspheres was added to this methanol
followed by using the vortex for 5 min to enhance the methanol penetration into all of the
pore spaces of the microspheres. Removal of the excess methanol which exceeded the 5 mL
mark was carried out before weighing the cylinder again. The final step was the recovery
of the microspheres from the methanol and recording the weight of the methanol along
with the cylinder. Finally, the porosity was calculated according to the following formula:
ε = (W2 − W3 − Ws)/(W1 − W3), where
W1 represents the weight of the cylinder filled with 5 mL of methanol before addition
of the microsphere sample, W2 represents the weight of the cylinder together with methanol
and the microsphere sample, after removal of the amount of methanol which exceeded the
5 mL mark, W3 represents the weight of the cylinder filled with methanol after removal
of the microsphere sample penetrated by methanol and Ws is the specific weight of the
microspheres sample added to the methanol [75].
4.3.3. Determination of Residual PVA content
Quantification of the residual polyvinyl alcohol depends on the ability of iodine
molecule to form a coloured complex between its adjacent hydroxyl groups [110]. This
quantification was carried out using 2 mg of empty control, Cl-amidine and control rho-
damine containing P(3HB) microspheres which were incubated with 2 mL of 0.5 M sodium
hydroxide (NaOH) in a water bath adjusted at 60 ◦C for 15 min. This was then neutralized
using 900 µL of 1 N hydrochloric acid (HCL). Finally, distilled water was added to adjust
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the volume to 5 mL followed by the addition of 3 mL of 0.65 M solution of boric acid, 0.5 mL
of iodine solution (I2)/Potassium iodide (KI) (0.05 M/0.15 M) and 1.5 mL of distilled water
to each type of the microsphere samples. Finally, this complex was incubated at room
temperature for 15 min and its absorbance was measured at 690 nm using the Novaspec II
Visible spectrophotometer (Fisher Scientific, Loughborough, UK). In addition, a standard
graph of PVA was developed under exactly the same conditions [75].
4.3.4. Determination of Surface Hydrophobicity
Empty P(3HB) microspheres (2 mg) with encapsulated Cl-amidine and control rho-
damine samples were incubated at room temperature with varying concentrations of Rose
Bengal dye, ranging from 0–50 µg/mL for a duration of 3 h. Controls were prepared using
dye solutions of the same concentrations used with the microspheres. Following incubation,
the samples of microspheres were centrifuged using a microcentrifuge (Sorvall legend
RT, Fisher Scientific, Loughborough, UK) at a speed of 12,000 rpm (g = 8064) for 10 min
duration. The absorbance of the unbound dye in the supernatant was measured at 542.7 nm
using the Novaspec II Visible spectrophotometer. Finally, the amount of Rose Bengal dye
adsorbed on the surface of the microspheres was determined using the prepared controls
as references.
4.3.5. Protein Adsorption Studies Using Bradford’s Assay
P(3HB) microspheres (2 mg), empty control, rhodamine control and with encapsulated
Cl-amidine samples were immersed in a BSA solution of 25 µg/mL concentration. Then,
the samples were incubated at 37 ◦C for 24 h. Simultaneously, standard dilutions of BSA
were treated under the same conditions to obtain the calibration curve. The samples
were centrifuged at 12,000 rpm (g = 8064). The Bradford reagent (Bio-Rad Laboratories,
Watford, UK) was added to the supernatant to carry out Bradford’s assay which was
used to determine the amount of unbound BSA. Briefly, 1 mL of Bradford’s reagent was
added to the supernatant of diluted samples and standards followed by incubation at room
temperature for 25 min. Finally, absorbance was measured at 280 nm to determine the
concentration of BSA in the supernatant such that the protein adsorbed on the surface of
the samples could be calculated using the following equation
Q = (Ci − Cf) V/m.
where Ci is the initial concentration of BSA, Cf is the final BSA concentration in the
supernatant after centrifugation while V is the total volume of the solution and m is the
weight of the samples.
4.4. In Vitro Drug Release Kinetics
The in vitro drug release kinetics were assessed over a period of 16 days using an
incubator with temperature maintained at 37 ◦C. P(3HB) microsphere samples which had
been encapsulated with 2 mg of Cl-amidine, were immersed in 2 mL of phosphate buffer
saline (PBS) prepared at pH of 7.4, used to mimic the blood plasma and body fluids due to
its isotonicity, and kept at 37 ◦C. Microsphere samples of 1 mL were drawn periodically in
triplicates and fresh PBS was added. Cl-amidine content of the samples was analysed using
UV spectrometry at 327 nm using the Lambda 35 UV/VIS Spectrometer, Perkin Elmer,
Beaconsfield, UK, and its concentration quantified using a standard curve.
4.5. Drug Quantification through Encapsulation Efficiency Calculation
The percentage drug encapsulation efficiency was calculated using the follow-
ing formula:
%EE = Experimental drug loading/Theoretical drug loading.
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To determine the EE values, 10 mg of the Cl-amidine encapsulated P(3HB) micro-
spheres were dissolved in 1 mL of chloroform, then vortexed for 10 min. In the case of the
hydrophilic drug Cl-amidine, 2 mL of Phosphate Buffer Saline (PBS) was added, and the
mixture was vortexed for further 10 min. This mixture was then centrifuged at 4600 rpm
for 10 min to separate out the hydrophilic Cl-amidine in the water phase where it was
quantified by UV spectrometry at 327 nm using the Lambda 35 UV/VIS Spectrometer,
PerkinElmer, Beaconsfield, UK.
4.6. Cell Culture
SK-BR-3 cells [111] were grown in DMEM media, supplemented with 10% foetal
calf serum, and 1% w/v penicillin and 1% w/v streptomycin solution, as described by
ATCC [112]. The medium was changed every 2–3 days. The cell cultures were maintained
at 37 ◦C, 5% CO2 and passaged based on 60–70% confluence, by trypsin treatment for
10 min. Following cell detachment, fresh medium was added to the cell suspension, which
was then centrifuged at 1000 rpm for 10 min. The resulting cell pellet was suspended in
fresh medium and transferred to 75 cm2 tissue culture flasks. Cells were seeded in 24-well
plates, with a density of 5 × 105/mL and incubated for 24 h to allow attachment.
Triplicates of SK-BR-3 cells were treated either with 1 mg/mL each of P(3HB) micro-
spheres with encapsulated Cl-amidine, with 5 ng/mL of rapamycin, or with a combination
of both 5 ng/mL of rapamycin and 1 mg/mL of microspheres with encapsulated Cl-
amidine. These were incubated for 24 h, whereas untreated SK-BR-3 cells were used as a
positive control, and cell viability was assessed using MTT assay [113].
Briefly, 100 µL of MTT reagent was added to each sample and incubated for 4 h. The
culture media was removed and 100 µL of DMSO was added and incubated for a further
2 h. The absorbance was read at 590 nm.
4.7. Effects on VEGF Expression
VEGF expression within the control (untreated) SK-BR-3 cells and those treated with
P(3HB) microspheres with encapsulated Cl-amidine was calculated using the VEGF human
ELISA kit, following the manufacturer’s protocol (Thermo Fisher Scientific, UK).The
samples and controls were added to ELISA plates with immobilized antibody. The VEGF
antibody complex (Thermo Fisher Scientific, Hemel Hempstead, UK) was washed using the
washing buffer to remove any unbound samples and then treated with a second detector
antibody with a conjugate enzyme that binds to a different epitope on the target antibody.
The microplates were then washed to remove any unbound substances and a substrate
specific to the enzyme, was added, forming a coloured complex. The absorbance of this
complex was read at 540 nm.
4.8. Statistical Analysis
All experiments were carried out in triplicate, and data was expressed accompanied
by their mean standard deviation (SD). Student’s t test, ANOVA and Bonferroni correction
tests were used to compare the data and to analyse significant differences among the
assessed factors. The significant differences were represented as * p < 0.05, ** p < 0.01 and
*** p < 0.001.
5. Conclusions
The current study developed a new drug delivery method for the pan-PAD inhibitor
Cl-amidine by encapsulation into Poly(3-hydroxybutyrate) microspheres. Cl-amidine
encapsulation in P(3HB) microspheres was optimized, and the release kinetics of Cl-
amidine from the microspheres were assessed in vitro and expressed as a function of
encapsulation efficiency. A burst release of ~50% Cl-amidine was observed in the first
24 h, followed by a zero-order release from that point up to 16 days, at which time point
~93% of the drug had been released. SK-BR-3 breast cancer cells treated with Cl-amidine
encapsulated microspheres were found to have 36.5% reduction in VEGF expression
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when compared with untreated SK-BR-3 cells, indicative of anti-cancerous effects via
controlled release of Cl-amidine from P(3HB) microspheres. Cl-amidine delivery via
P(3HB) microspheres may provide both controlled and prolonged release delivery of this
PAD inhibitor in cancer as well as in a range of other PAD-related diseases, including
neurodegenerative and autoimmune pathologies. Future studies will need to assess the
reported P(3HB) microspheres with encapsulated Cl-amidine in further in vitro and in vivo
models, as well as testing this controlled drug delivery system for other PAD inhibitors.
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